News|Articles|February 23, 2024
NeurologyLive® Friday 5 — February 23, 2024
Author(s)NeurologyLive® Staff
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 23, 2024.
Advertisement
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
1: Recognizing and Addressing Comorbidities in Complex Headache Disorders: Svetlana Blitshteyn, MD, FAAN
The director of Dysautonomia Clinic talked about the importance of focusing beyond migraine to address often overlooked comorbidities such as dysautonomia, hypermobility spectrum disorders, and mast cell activation syndrome. [WATCH TIME: 10 minutes]
2: New Directions and Practice Impacting Recommendations in Multiple Sclerosis
This publication presents a collection of insights and takeaways from presentations with the goal of bridging the gaps between new developments and their application in practice for multiple sclerosis.
3: Highlights of ISC 2024, Trials and Future Innovations for Stroke Care: Tudor Jovin, MD; Lauren Sansing, MD, MS, FAHA
The medical director of the Cooper Neurological Institute and the professor of neurology at Yale University School of Medicine shared a few highlights from research presented at ISC 2024. [WATCH TIME: 7 minutes]
4: NeuroVoices: Rita Sattler, MD, MSc, on 2024 MDA Conference and Advances in ALS Research
In this week's NeuroVoices Q&A, the professor in the Department of Translational Neuroscience at Barrow Neurological Institute discussed several topics related to ALS research and the emerging biomarkers in recent years ahead of the 2024 MDA Clinical and Scientific Conference.
5: Neurofilament Light Chain and MS Prognosis, Treatment Effect, and Anticipation of Disease
In a new episode of the "CMSC Consensus Panel Guidance on the Use of Serum Neurofilament Light Chain in the Management of Multiple Sclerosis" video series, Mark Freedman, MD, MSc, Tanuja Chitnis, MD, and Ahmed Obeidat, MD, PhD, contextualize data from large studies regarding the utilization of neurofilament light chain.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
NeurologyLive® Friday 5 — September 12, 2025September 12th 2025
Expanding the Alzheimer Drug Development PipelineSeptember 12th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
Expanding the Alzheimer Drug Development Pipeline
2
DORAs Carry Lower Real-World Abuse, New Phase 3 Argus Data, RAP-219 Meets Primary End Point
3
FDA Hands Complete Response Letter to SL1009 for Pyruvate Dehydrogenase Complex Deficiency
4
Patient-Reported Study Identifies Common Symptoms and Timing During Migraine Prodrome
5
